• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical rheumatology >Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry
【24h】

Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry

机译：Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相关主题

摘要

Despite improved quality of care for rheumatoid arthritis (RA) patients, many still experience treatment failure with a biologic agent and eventually switch to another biologic agent. We investigated patterns of biologic treatment and reasons for switching biologics in patients with RA. Patients with RA who had started on a biologic agent or had switched to another biologic agent were identified from the prospective observational Korean nationwide Biologics (KOBIO) registry. The KOBIO registry contained 1184 patients with RA at the time of initiation or switching of biologic agents. Patients were categorized according to the chronological order of the introduction of biologic agents, and reasons for switching biologics were also evaluated. Of the 1184 patients with RA, 801 started with their first biologic agent, 228 were first-time switchers, and 89 were second-time or more switchers. Second-time or more switchers had lower rheumatoid factor and anti-CCP positivity, and higher disease activity scores at the time of enrollment than the other groups. Among these patients, tocilizumab was the most commonly prescribed biologic agent, followed by adalimumab and etanercept. The most common reason for switching biologics was inefficacy, followed by adverse events, including infusion reactions, infections, and skin eruptions. Furthermore, the proportion of inefficacy, as a reason for switching, was significantly higher with respect to switching between biologics with different mechanisms of action than between biologics with similar mechanisms. In this registry, we showed diverse prescribing patterns and differing baseline profiles based on the chronological order of biologic agents.

著录项

  • 来源
    《Clinical rheumatology》 |2017年第5期|1013-1022|共10页
  • 作者

    Park Dong-Jin; Choi Sung Jae; Shin KichulKim Hyoun-AhPark Yong-BeomKang Seong WookKwok Seung-KiKim Seong-KyuNam Eon JeongSung Yoon-KyoungLee JaejoonLee Chang HoonJeon Chan HongLee Shin-Seok;

  • 作者单位

    Ajou Univ, Sch Med, Ajou Univ Hosp, Dept Rheumatol, Suwon, South Korea;

    Yonsei Univ, Div Rheumatol, Dept Internal Med, Seoul, South Korea;

    Chungnam Natl Univ, Dept Internal Med, Sch Med, Daejeon, South KoreaCatholic Univ Korea, Coll Med, Seoul St Mary Hosp S, Div Rheumatol,Dept Internal Med, Seoul, SouthCatholic Univ Daegu, Dept Internal Med, Sch Med, Daegu, South KoreaKyungpook Natl Univ, Dept Internal Med, Sch Med, Daegu, South KoreaHanyang Univ Hosp Rheumat Dis, Dept Rheumatol, Seoul, South KoreaSungkyunkwan Univ, Dept Med, Samsung Med Ctr, Sch Med, Seoul, South KoreaWonkwang Univ, Sch Med, Div Rheumatol, Dept Internal Med, Iksan, South KoreaSoonchunhyang Univ Hosp, Div Rheumatol, Dept Internal Med, Bucheon, South KoreaChonnam Natl Univ Hosp & Med Sch, Dept Rheumatol, 42 Jebong Ro, Gwangju 61469, South KoreaKorea Univ, Div Rheumatol, Dept Internal Med, Ansan Hosp, Ansan, South KoreaSeoul Natl Univ, Boramae Med Ctr, Seoul Metropolitan Govt, Dept Internal Med, Seoul, South Korea;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 英语
  • 中图分类 内科学;
  • 关键词

    Biologic agents; Registry; Rheumatoid arthritis; Switching;

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号